Implications of the obesity epidemic for lipid-lowering therapy: Non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target

Overview of attention for article published in Vascular Health and Risk Management, February 2008

Altmetric Badge

Mentioned by

patent: 1 patent

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 1 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

EXENDIN AND EXENDIN AGONISTS FOR EATING DISORDERS

Application US-20130023470-A1

United States of America